A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Type 2 Diabetes Patients
Interventions
DRUG

PF-04620110

5 mg of PF-04620110 given once daily

DRUG

PF-04620110

2.5 mg of PF-04620110 given twice daily

DRUG

Placebo

Matching placebo giving for 4 weeks

Trial Locations (3)

32720

Pfizer Investigational Site, DeLand

33169

Pfizer Investigational Site, Miami Gardens

91911

Pfizer Investigational Site, Chula Vista

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01298518 - A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients | Biotech Hunter | Biotech Hunter